

**Poster Session B**  
**Saturday, September 7**  
**1:30 p.m.-3:30 p.m.**

**B01 Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma.** Christine C. Alewine, National Cancer Institute, NIH, Bethesda, MD

**B02 Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy.** Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY

**B03 Targeting tumor-intrinsic metabolic node in pancreatic cancer causes tumor regression, remodels extracellular matrix, and sensitizes to anti-PD1 therapy.** Sulagna Banerjee, University of Miami, Miami, FL

**B04 Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer.** Adham S. Bear, University of Pennsylvania, Philadelphia, PA

**B05 Paclitaxel protein bound plus gemcitabine plus cisplatin and paricalcitol neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).** Erkut Borazanci, HonorHealth/TGen, Scottsdale/Phoenix, AZ

**B06 The angiotensin receptor blocker and partial PPAR $\gamma$  agonist telmisartan inhibits the growth of pancreatic ductal adenocarcinoma.** Yves Boucher, Massachusetts General Hospital, Harvard Medical School, Boston, MA

**B07 Enhancing the effect of autophagy inhibition for pancreatic cancer treatment.** Kirsten L. Bryant, University of North Carolina at Chapel Hill, Chapel Hill, NC


**B08 STING and TLR independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody.** Katelyn T. Byrne, Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**B09 GSK-3 $\beta$  blockade with 9-ING-41 in pancreas cancer: The 1801 phase 1/2 study.** Benedito A. Carneiro, Lifespan Cancer Institute, Brown University, Providence, RI

**B10 Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma.** Eileen Carpenter<sup>1</sup>, Department of Gastroenterology, University of Michigan, Ann Arbor, MI

**B11 circFOXK2 promotes tumor growth and metastasis of pancreatic ductal adenocarcinoma via complexing with YBX1 and hnRNPk.** Yangchao Chen, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong

**B13 Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer.** Vincent Chung, City of Hope, Duarte, CA



**Poster Session B**  
**Saturday, September 7**  
**1:30 p.m.-3:30 p.m.**

**B14 CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX).** Fiona Maxwell, Ipsen Bioinnovation, Abingdon, UK

**B15 Therapeutic potential of targeting amino acid metabolism in pancreatic cancer.** Giuseppe Del Priore<sup>4</sup>, Tyme Inc., New York, NY

**B16 CTC-based efficacy of SM-88 correlates with overall survival in advanced pancreatic cancer.** Giuseppe Del Priore, Tyme Inc., New York, NY

**B17 Long noncoding RNA growth arrest specific 5 (GAS5) as a proliferation "brake" in aggressive population of CD133+ cells responsible for recurrence in PDAC.** Brittany C. Durden, University of Miami, Miami, FL

**B18 Defining the role of chromatin remodeling complexes in pancreatic cancer stem cells.** Lesley Paige Ferguson, University of California San Diego, La Jolla, CA

**B19 Targeting ATM to sensitize pancreatic cancer to immunotherapy and radiotherapy.** Michael Green, University of Michigan, Ann Arbor, MI

**B20 Kras<sup>G12D</sup> effector dependencies in the maintenance of pancreatic ductal adenocarcinoma.** Adrien Grimont, Weill Cornell Medicine, New York, NY

**B21 Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma.** Christopher Natale, Linnaeus Therapeutics, Haddonfield, NJ

**B22 Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).** Hagop Youssoufian, Erytech, Boston, MA


**B23 Bioadhesive nanoparticles as a delivery vehicle in pancreatic cancer epithelial cells and pancreatic fibroblasts.** Nesrin M. Hasan, Yale University, New Haven, CT

**B24 Gastrointestinal microbiome changes in stage IV pancreatic cancer patients treated with pembrolizumab with or without paricalcitol on the Stand Up to Cancer (SU2C) Pancreas Catalyst Trial.** Sarah K. Highlander, Translational Genomics Research Institute, Flagstaff, AZ

**B25 Engrailed-1 promotes pancreatic cancer progression via antagonizing COMPASS activity.** Chang-il Hwang, University of California Davis, Davis, CA


**B26 Targeted and sustained drug delivery therapy for localized pancreatic cancer: In vivo validation in porcine models.** Laura Indolfi, PanTher Therapeutics, Inc., Cambridge, MA

**B27 A phase Ib/II trial of high-dose (HD) ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (MPC).** Gayle S. Jameson, HonorHealth Research Institute, Scottsdale, AZ




**Poster Session B**  
**Saturday, September 7**  
**1:30 p.m.-3:30 p.m.**

- B28 Novel combination treatment designed to target both metastatic cells and proliferation in pancreatic ductal adenocarcinoma.** Michelle Karl, Johns Hopkins University, Baltimore, MD
- B29 Outcomes of DNA repair-deficient pancreatic cancers: KU Cancer Center experience.** Anup Kasi, University of Kansas, Kansas City, KS
- B30 Assessment of CCR5i/maraviroc immunotherapy in combination with PD1 and MR-guided radiotherapy for treatment of pancreatic cancer.** Simone Lanfredini, University of Oxford, Oxford, United Kingdom
- B31 Type 1 conventional dendritic cells are progressively and systemically dysregulated early in pancreatic carcinogenesis.** Jeffrey H. Lin, University of Pennsylvania, Philadelphia, PA
- B32 Mutant KRAS downregulates LIFR to enhance glycolysis in pancreatic cancer.** Suhu Liu, Montefiore New Rochelle Hospital, New Rochelle, NY
- B33 Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) in pancreatic adenocarcinoma.** Nune Markosyan, University of Pennsylvania, Philadelphia, PA
- B34 The impact of lymphocyte-to-monocyte ratio (LMR) in patients with borderline resectable pancreatic head cancer after curative surgery.** Yoji Miyahara, Department of General Surgery, Chiba University, Chiba, Japan
- B35 Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging.** Jonathan D. Mizrahi, University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2</sup>University of Arizona Cancer Center, Tucson, AZ
- B36 Maintenance chemotherapy after chemoradiation in patients with locally advanced pancreatic cancer.** Jonathan D. Mizrahi, University of Texas MD Anderson Cancer Center, Houston, TX
- B37 The complex immune-microenvironment heterogeneity in pancreatic cancer.** Dana A. Mustafa, Erasmus MC, Rotterdam, The Netherlands
- B38 Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma.** Robert J. Norgard, University of Pennsylvania, Philadelphia, PA
- B40 High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial.** Eric O'Neill, Oxford University, Oxford, United Kingdom
- B41 Compartment deconvolution in pancreatic cancer with biologic and clinical implications.** Xianlu L. Peng, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
- B42 Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment.** Didier Ritter, Acobiom, Montpellier, France



**Poster Session B**  
**Saturday, September 7**  
**1:30 p.m.-3:30 p.m.**

- B43 p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of PTHrP-mediated calcium signaling.** Jason R. Pitarresi, University of Pennsylvania, Philadelphia, PA
- B44 Clinical utility of semiquantitative evaluation of progesterone receptor immunohistochemistry in neuroendocrine tumors of the pancreas.** Sonya Purushothaman, Columbia Presbyterian Hospital, New York, NY
- B45 IL35/STAT3 axis as regulator of tolerance and T-cell exclusion in pancreatic cancer.** Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC
- B46 Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734.** Nikolina Radulovich, University Health Network, Toronto, ON, Canada
- B47 KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL.** Cody Rozeveld, Mayo Clinic, Rochester, MN
- B48 Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma.** Luis I. Ruffolo, University of Rochester Medical Center, Rochester, NY
- B49 Precision targeting of M2-like macrophages by the innate defense regulator RP-182 in pancreatic cancer and noncancerous diseases.** Rushikesh Sable, National Cancer Institute, Bethesda, MD
- B50 Keratin 17 drives tumor aggression and could be targeted for treatment of pancreatic ductal adenocarcinoma.** Kenneth R. Shroyer, Department of Pathology, Renaissance School of Medicine, Stony Brook, NY
- B51 Examining the differential cellular response of pancreatic cancer cell lines to 12C vs. photon irradiation.** Brock J. Sishc, UT Southwestern Medical Center, Dallas, TX
- B52 The T-cell architecture of pancreatic ductal adenocarcinoma.** Shivan Sivakumar, University of Oxford, Oxford, United Kingdom
- B54 The clinical impact and analysis for neoadjuvant chemotherapy against borderline resectable pancreatic cancer: Gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel.** Shigetsugu Takano, Chiba University, Chiba, Japan
- B56 Endogenous retrovirus transcript levels are associated with immunogenic signatures in multiple metastatic cancer types.** James T. Topham, Pancreas Centre BC, Vancouver, BC, Canada
- B57 Early-onset pancreatic ductal adenocarcinomas are characterized by a distinct mutational landscape.** Erica S. Tsang, BC Cancer, Vancouver, BC, Canada
- B58 A phase I/II study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer.** Richard Tuli, Memorial Sloan Kettering Cancer Center, New York, NY



**Poster Session B**

**Saturday, September 7**

**1:30 p.m.-3:30 p.m.**

**B59 IL-6 regulates CTLA4 expression on CD4+ T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma.** Michael B. Ware, Emory University, Atlanta, GA

**B60 Optimization of biologic scheduling of gemcitabine and abraxane improves treatment response compared to the standard concurrent regimen in preclinical models of pancreatic cancer.** Adam R. Wolfe, Ohio State James Cancer Center, Columbus, OH

**B61 Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules.** Keisuke Yamamoto, Department of Radiation Oncology, New York University School of Medicine, New York, NY

**B62 Development of infectivity-selective oncolytic adenovirus for systemic cancer therapy.** Masato Yamamoto, University of Minnesota, Minneapolis, MN